NASDAQ:AGTC - Applied Genetic Technologies Stock Price, Price Target & More

$4.70 -0.15 (-3.09 %)
(As of 04/26/2018 03:30 AM ET)
Previous Close$4.85
Today's Range$4.65 - $4.85
52-Week Range$3.25 - $6.05
Volume49,600 shs
Average Volume105,429 shs
Market Capitalization$92.33 million
P/E Ratio235.00
Dividend YieldN/A
Beta2.1

About Applied Genetic Technologies (NASDAQ:AGTC)

Applied Genetic Technologies logoApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGTC
CUSIPN/A
Phone386-462-2204

Debt

Debt-to-Equity RatioN/A
Current Ratio6.49%
Quick Ratio6.49%

Price-To-Earnings

Trailing P/E Ratio235.00
Forward P/E Ratio-3.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.47 million
Price / Sales2.16
Cash Flow$0.0671 per share
Price / Cash70.03
Book Value$6.38 per share
Price / Book0.74

Profitability

EPS (Most Recent Fiscal Year)$0.02
Net Income$400,000.00
Net Margins-33.24%
Return on Equity-9.21%
Return on Assets-7.35%

Miscellaneous

Employees72
Outstanding Shares18,100,000

How to Become a New Pot Stock Millionaire

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) issued its earnings results on Friday, February, 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.20. The biotechnology company had revenue of $4.85 million for the quarter, compared to analysts' expectations of $8.72 million. Applied Genetic Technologies had a negative return on equity of 9.21% and a negative net margin of 33.24%. The business's quarterly revenue was down 55.5% on a year-over-year basis. During the same period last year, the company posted $0.10 earnings per share. View Applied Genetic Technologies' Earnings History.

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Applied Genetic Technologies.

What price target have analysts set for AGTC?

5 brokers have issued 12 month price objectives for Applied Genetic Technologies' shares. Their predictions range from $7.00 to $12.00. On average, they anticipate Applied Genetic Technologies' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Applied Genetic Technologies.

What are Wall Street analysts saying about Applied Genetic Technologies stock?

Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
  • 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (3/30/2018)
  • 2. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017)

Who are some of Applied Genetic Technologies' key competitors?

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the folowing people:
  • Ms. Susan B. Washer, Pres, CEO & Director (Age 57)
  • Dr. Mark S. Shearman Ph.D., Chief Scientific Officer (Age 58)
  • Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 62)
  • Dr. Jeffrey D. Chulay, Exec. Director of Clinical Strategy (Age 71)
  • Dr. Nicholas Muzyczka, Co-Founder

Has Applied Genetic Technologies been receiving favorable news coverage?

News coverage about AGTC stock has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $4.70.

How big of a company is Applied Genetic Technologies?

Applied Genetic Technologies has a market capitalization of $92.33 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.


MarketBeat Community Rating for Applied Genetic Technologies (AGTC)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Applied Genetic Technologies (NASDAQ:AGTC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Applied Genetic Technologies in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 91.49%. The high price target for AGTC is $12.00 and the low price target for AGTC is $7.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.832.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$10.1667$11.7143
Price Target Upside: 91.49% upside133.77% upside157.38% upside192.86% upside

Applied Genetic Technologies (NASDAQ:AGTC) Consensus Price Target History

Price Target History for Applied Genetic Technologies (NASDAQ:AGTC)

Applied Genetic Technologies (NASDAQ:AGTC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018WedbushReiterated RatingOutperformHighView Rating Details
2/9/2018HC WainwrightSet Price TargetBuy$8.00LowView Rating Details
1/17/2018Cantor FitzgeraldReiterated RatingHold$9.00LowView Rating Details
9/14/2017BMO Capital MarketsReiterated RatingOutperform$14.00 -> $7.00HighView Rating Details
9/14/2017Stifel NicolausLower Price TargetBuy -> Buy$15.00 -> $12.00HighView Rating Details
3/15/2017Rodman & RenshawInitiated CoverageBuy -> Buy$16.00HighView Rating Details
11/9/2016Roth CapitalUpgradeNeutral -> Buy$12.00 -> $15.00N/AView Rating Details
9/26/2016Janney Montgomery ScottUpgradeSell -> Neutral$11.00N/AView Rating Details
9/13/2016Wells FargoDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Applied Genetic Technologies (NASDAQ:AGTC) Earnings History and Estimates Chart

Earnings by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Applied Genetic Technologies (NASDAQ:AGTC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.73)($0.73)($0.73)

Applied Genetic Technologies (NASDAQ AGTC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
2/9/2018Q2 2018($0.09)($0.2870)$8.72 million$4.85 millionViewListenView Earnings Details
11/7/2017Q1 2018($0.14)($0.08)$8.62 million$10.32 millionViewN/AView Earnings Details
9/13/2017Q4 2017$0.22($0.18)$12.39 million$8.30 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.0140)($0.05)$10.39 million$8.39 millionViewN/AView Earnings Details
2/8/2017Q217$0.02$0.11$11.10 million$10.90 millionViewListenView Earnings Details
11/8/2016Q117($0.10)$0.20$10.21 million$11.80 millionViewListenView Earnings Details
9/12/2016Q416$0.07$0.15$13.10 million$12.10 millionViewListenView Earnings Details
5/9/2016Q3$0.05$0.11$12.98 million$12.00 millionViewN/AView Earnings Details
2/8/2016Q216($0.19)$0.17$8.76 million$12.20 millionViewN/AView Earnings Details
11/5/2015Q1($0.20)($0.53)$5.91 million$11.06 millionViewN/AView Earnings Details
9/10/2015Q415($0.41)($0.48)$0.63 million$0.71 millionViewN/AView Earnings Details
5/11/2015Q315($0.33)($0.38)$0.59 million$0.28 millionViewN/AView Earnings Details
2/11/2015Q215($0.39)($0.28)$0.45 million$0.65 millionViewN/AView Earnings Details
11/12/2014Q115($0.29)($0.34)$258.00 million$705.00 millionViewN/AView Earnings Details
9/26/2014Q414($0.29)($0.32)$0.23 million$0.12 millionViewN/AView Earnings Details
5/14/2014Q114($0.37)($25.45)$0.15 million$0.2320 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Applied Genetic Technologies (NASDAQ:AGTC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Applied Genetic Technologies (NASDAQ AGTC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 46.23%
Insider Trading History for Applied Genetic Technologies (NASDAQ:AGTC)
Institutional Ownership by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Applied Genetic Technologies (NASDAQ AGTC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2016Ivana MagovcevicDirectorBuy3,000$9.63$28,890.003,000View SEC Filing  
11/1/2016Jeffrey D ChulayVPSell1,000$7.05$7,050.0020,400View SEC Filing  
9/22/2016Mark S ShearmanInsiderBuy3,000$8.87$26,610.001,700View SEC Filing  
9/20/2016Stephen W PotterInsiderBuy1,400$8.89$12,446.001,000View SEC Filing  
9/19/2016Lawrence E BullockCFOBuy10,000$8.75$87,500.0010,000View SEC Filing  
2/23/2015Plc GlaxosmithklineMajor ShareholderSell503,150$22.00$11,069,300.00View SEC Filing  
1/23/2015Daniel L MenichellaVPSell1,996$24.90$49,700.40View SEC Filing  
12/22/2014Daniel L MenichellaVPSell9,000$20.83$187,470.00View SEC Filing  
4/1/2014Interwest Partners Viii LpMajor ShareholderBuy75,376$12.00$904,512.00View SEC Filing  
4/1/2014Jill CarrollDirectorBuy103,762$12.00$1,245,144.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Applied Genetic Technologies (NASDAQ AGTC) News Headlines

Source:
DateHeadline
Applied Genetic Technologies Co. (AGTC) Expected to Announce Quarterly Sales of $6.21 MillionApplied Genetic Technologies Co. (AGTC) Expected to Announce Quarterly Sales of $6.21 Million
www.americanbankingnews.com - April 19 at 3:06 AM
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis PigmentosaAGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
finance.yahoo.com - April 18 at 8:11 AM
Zacks: Analysts Expect Applied Genetic Technologies Co. (AGTC) to Post -$0.25 Earnings Per ShareZacks: Analysts Expect Applied Genetic Technologies Co. (AGTC) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - April 17 at 1:19 PM
AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
finance.yahoo.com - April 10 at 5:34 PM
$6.21 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter$6.21 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - April 2 at 3:06 AM
Applied Genetic Technologies Corp (AGTC) Receives Average Rating of "Hold" from AnalystsApplied Genetic Technologies Corp (AGTC) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 9:36 AM
Applied Genetic Technologies (AGTC) Rating Lowered to Strong Sell at ValuEngineApplied Genetic Technologies (AGTC) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 31 at 3:48 PM
 Brokerages Anticipate Applied Genetic Technologies Corp (AGTC) to Post -$0.25 Earnings Per Share Brokerages Anticipate Applied Genetic Technologies Corp (AGTC) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - March 31 at 1:21 PM
Zacks Investment Research Upgrades Applied Genetic Technologies (AGTC) to "Hold"Zacks Investment Research Upgrades Applied Genetic Technologies (AGTC) to "Hold"
www.americanbankingnews.com - March 30 at 4:32 PM
Applied Genetic Technologies (AGTC) Downgraded to "Sell" at Zacks Investment ResearchApplied Genetic Technologies (AGTC) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:04 PM
Applied Genetic Technologies Corp (AGTC) Expected to Announce Earnings of -$0.25 Per ShareApplied Genetic Technologies Corp (AGTC) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - March 14 at 11:27 AM
Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis ... - Business Wire (press release)Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis ... - Business Wire (press release)
www.businesswire.com - March 13 at 8:17 AM
Head to Head Analysis: Vascular Biogenics (VBLT) versus Applied Genetic Technologies (AGTC)Head to Head Analysis: Vascular Biogenics (VBLT) versus Applied Genetic Technologies (AGTC)
www.americanbankingnews.com - March 12 at 3:10 AM
Applied Genetic Technologies Corp (AGTC) Receives Consensus Rating of "Hold" from AnalystsApplied Genetic Technologies Corp (AGTC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 7 at 2:02 PM
ValuEngine Downgrades Applied Genetic Technologies (AGTC) to Strong SellValuEngine Downgrades Applied Genetic Technologies (AGTC) to Strong Sell
www.americanbankingnews.com - March 5 at 12:48 AM
Applied Genetic Technologies Corp (AGTC) Expected to Announce Quarterly Sales of $6.21 MillionApplied Genetic Technologies Corp (AGTC) Expected to Announce Quarterly Sales of $6.21 Million
www.americanbankingnews.com - February 27 at 7:58 AM
-$0.25 Earnings Per Share Expected for Applied Genetic Technologies Corp (AGTC) This Quarter-$0.25 Earnings Per Share Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - February 25 at 11:58 AM
Applied Genetic Technologies (AGTC) Earns Outperform Rating from WedbushApplied Genetic Technologies (AGTC) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - February 18 at 9:50 PM
AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization’s Board of DirectorsAGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization’s Board of Directors
finance.yahoo.com - February 15 at 9:16 AM
FY2018 Earnings Forecast for Applied Genetic Technologies Corp (AGTC) Issued By Cantor FitzgeraldFY2018 Earnings Forecast for Applied Genetic Technologies Corp (AGTC) Issued By Cantor Fitzgerald
www.americanbankingnews.com - February 14 at 11:38 AM
Wired News – Catalyst Biosciences Shares Positive Top-line Data from Phase-1/2 Study of Subcutaneous CB 2679d for Hemophilia BWired News – Catalyst Biosciences Shares Positive Top-line Data from Phase-1/2 Study of Subcutaneous CB 2679d for Hemophilia B
finance.yahoo.com - February 12 at 9:07 AM
Applied Genetic Technologies Corp (AGTC) Receives Average Recommendation of "Hold" from BrokeragesApplied Genetic Technologies Corp (AGTC) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 9:44 AM
 Analysts Anticipate Applied Genetic Technologies Corp (AGTC) Will Announce Quarterly Sales of $10.92 Million Analysts Anticipate Applied Genetic Technologies Corp (AGTC) Will Announce Quarterly Sales of $10.92 Million
www.americanbankingnews.com - February 10 at 2:48 AM
Applied Genetic Technologies (AGTC) PT Set at $8.00 by HC WainwrightApplied Genetic Technologies (AGTC) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - February 9 at 4:10 PM
Applied Genetic Technologies (AGTC) Releases  Earnings Results, Misses Estimates By $0.20 EPSApplied Genetic Technologies (AGTC) Releases Earnings Results, Misses Estimates By $0.20 EPS
www.americanbankingnews.com - February 9 at 10:26 AM
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017
finance.yahoo.com - February 9 at 9:13 AM
Applied Genetic Technologies Corp. to Host Earnings CallApplied Genetic Technologies Corp. to Host Earnings Call
finance.yahoo.com - February 9 at 9:13 AM
Applied Genetic Technologies posts 2Q lossApplied Genetic Technologies posts 2Q loss
finance.yahoo.com - February 9 at 9:13 AM
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018
finance.yahoo.com - February 2 at 8:44 AM
Applied Genetic Technologies (AGTC) to Release Quarterly Earnings on TuesdayApplied Genetic Technologies (AGTC) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 2:56 AM
$10.92 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter$10.92 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - January 24 at 2:58 AM
Cantor Fitzgerald Reaffirms Hold Rating for Applied Genetic Technologies (AGTC)Cantor Fitzgerald Reaffirms Hold Rating for Applied Genetic Technologies (AGTC)
www.americanbankingnews.com - January 18 at 1:50 PM
Applied Genetic Technologies Corp (AGTC) Given Average Rating of "Hold" by AnalystsApplied Genetic Technologies Corp (AGTC) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 16 at 10:32 AM
Zacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $10.92 MillionZacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $10.92 Million
www.americanbankingnews.com - January 7 at 6:38 AM
Zacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Earnings of -$0.09 Per ShareZacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - January 5 at 5:32 PM
Analysts Issue Forecasts for Applied Genetic Technologies Corporations FY2019 Earnings (AGTC)Analysts Issue Forecasts for Applied Genetic Technologies Corporation's FY2019 Earnings (AGTC)
www.americanbankingnews.com - January 4 at 11:40 PM
ETFs with exposure to Applied Genetic Technologies Corp. : December 25, 2017ETFs with exposure to Applied Genetic Technologies Corp. : December 25, 2017
finance.yahoo.com - December 25 at 4:14 PM
Zacks: Brokerages Anticipate Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $10.92 MillionZacks: Brokerages Anticipate Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $10.92 Million
www.americanbankingnews.com - December 22 at 9:20 PM
Applied Genetic Technologies Corporation (AGTC) Given Average Recommendation of "Hold" by AnalystsApplied Genetic Technologies Corporation (AGTC) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 22 at 10:28 AM
-$0.09 EPS Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter-$0.09 EPS Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - December 20 at 5:14 AM
ETFs with exposure to Applied Genetic Technologies Corp. : December 12, 2017ETFs with exposure to Applied Genetic Technologies Corp. : December 12, 2017
finance.yahoo.com - December 12 at 3:37 PM
AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017 - GlobeNewswire (press release)AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017 - GlobeNewswire (press release)
globenewswire.com - December 12 at 11:56 AM
AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017
feeds.benzinga.com - December 11 at 4:49 PM
$10.92 Million in Sales Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter$10.92 Million in Sales Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - December 4 at 11:02 AM
ETFs with exposure to Applied Genetic Technologies Corp. : December 1, 2017ETFs with exposure to Applied Genetic Technologies Corp. : December 1, 2017
finance.yahoo.com - December 1 at 4:30 PM
Applied Genetic Technologies Corporation (AGTC) Given Consensus Recommendation of "Hold" by BrokeragesApplied Genetic Technologies Corporation (AGTC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:00 PM
ETFs with exposure to Applied Genetic Technologies Corp. : November 20, 2017ETFs with exposure to Applied Genetic Technologies Corp. : November 20, 2017
finance.yahoo.com - November 20 at 5:07 PM
Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q1, 2018 By the Numbers : November 15, 2017Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q1, 2018 By the Numbers : November 15, 2017
finance.yahoo.com - November 16 at 10:52 AM
-$0.09 Earnings Per Share Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter-$0.09 Earnings Per Share Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - November 14 at 1:28 AM
Brokers Set Expectations for Applied Genetic Technologies Corporations Q3 2018 Earnings (AGTC)Brokers Set Expectations for Applied Genetic Technologies Corporation's Q3 2018 Earnings (AGTC)
www.americanbankingnews.com - November 13 at 7:54 AM

SEC Filings

Applied Genetic Technologies (NASDAQ:AGTC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Applied Genetic Technologies (NASDAQ:AGTC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Applied Genetic Technologies (NASDAQ AGTC) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.